A securities class action has been filed in the USDC – S.D.N.Y. against Dexcom, Inc. (DXCM) (“DexCom” or the “Company”), on behalf of all persons and entities that purchased or otherwise acquired DexCom common stock between January 8, 2024, and September 17, 2025, both dates inclusive (the “Class Period”).
Dexcom develops, manufactures, and markets continuous glucose monitors (“CGMs”). In early 2023, Dexcom launched the latest generation of its CGM, which it called the G7.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:
(1) DexCom had made material design changes to the G6 and G7 unauthorized by the U.S. Food and Drug Administration (the “FDA”);
(2) the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings;
(3) accordingly, Defendants’ purported enhancements to the G7, as well as the device’s reliability, accuracy, and functionality, were overstated;
(4) Defendants downplayed the true scope and severity of the issues and health risks posed by adulterated G7 devices; and
(5) all the foregoing subjected DexCom to an increased risk of heightened regulatory scrutiny and enforcement action, as well as significant legal, reputational, and financial harm.
DexCom’s stock price fell $8.99 per share, or 11.76%, over the following two trading sessions, to close at $67.45 per share on September 19, 2025.
If you purchased DexCom common stock during the Class Period, and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.